Compare UTF & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2004 | 2000 |
| Metric | UTF | SRPT |
|---|---|---|
| Price | $26.90 | $16.12 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 28 |
| Target Price | N/A | ★ $25.48 |
| AVG Volume (30 Days) | 370.3K | ★ 2.1M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $22.05 | $10.42 |
| 52 Week High | $27.33 | $107.23 |
| Indicator | UTF | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 34.08 |
| Support Level | $26.65 | $15.51 |
| Resistance Level | $27.18 | $19.55 |
| Average True Range (ATR) | 0.30 | 0.78 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 53.72 | 11.69 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.